Joel Greenblatt acquired 47.4 Thousand Halozyme Therapeutics shares worth $3.12 Million. That's 0.03% of their equity portfolio (581st largest holding). The first Halozyme Therapeutics trade was made in Q2 2015. Since then Joel Greenblatt bought shares fifteen more times and sold shares on fifteen occasions. The stake costed the investor $1.88 Million, netting the investor a gain of 66% so far.